Literature DB >> 8066566

Survival of patients with severe alpha 1-antitrypsin deficiency with special reference to non-index cases.

N Seersholm1, A Kok-Jensen, A Dirksen.   

Abstract

BACKGROUND: Previous estimates of the survival times of patients with alpha 1-antitrypsin deficiency have been based on selected patients.
METHODS: The survival times of 397 patients with severe alpha 1-antitrypsin deficiency identified by pulmonary impairment (index cases) or through family studies (non-index cases) were compared.
RESULTS: The overall median survival time was 54.5 years with no significant difference between men and women. Survival for index cases was less than for the non-index cases regardless of smoking history (49.4 years and 69.3 years respectively). When index and non-index cases were analysed separately there was no difference between the survival of smokers and never smokers in the index group. In the non-index group smokers had a shorter survival time than never smokers. The survival time of never smokers was similar to that of the normal Danish population.
CONCLUSIONS: The prognosis of severe alpha 1-antitrypsin deficiency is better than previously assumed and, although smoking is a major risk factor, the development of emphysema in patients with severe alpha 1-antitrypsin deficiency is multifactorial.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8066566      PMCID: PMC475060          DOI: 10.1136/thx.49.7.695

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  17 in total

Review 1.  Development and prognosis of chronic obstructive pulmonary disease with special reference to the role of tobacco smoking. An epidemiologic study.

Authors:  P Lange
Journal:  Dan Med Bull       Date:  1992-02

2.  Studies in alpha 1-antitrypsin deficiency.

Authors:  S Eriksson
Journal:  Acta Med Scand Suppl       Date:  1965

3.  alpha 1-antitrypsin deficiency in early childhood.

Authors:  T Sveger
Journal:  Pediatrics       Date:  1978-07       Impact factor: 7.124

4.  Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z.

Authors:  C Larsson
Journal:  Acta Med Scand       Date:  1978

5.  [Autoimmune pemphigus combined with alpha 1-antitrypsin deficiency].

Authors:  L Vaillant; M C Weisbecker; A de Muret; G Lorette
Journal:  Ann Dermatol Venereol       Date:  1988       Impact factor: 0.777

6.  Variability of pulmonary function in alpha-1-antitrypsin deficiency: residual family resemblance beyond the effect of the Pi locus.

Authors:  E K Silverman; M A Province; E J Campbell; J A Pierce; D C Rao
Journal:  Hum Hered       Date:  1990       Impact factor: 0.444

7.  Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms.

Authors:  M L Brantly; L D Paul; B H Miller; R T Falk; M Wu; R G Crystal
Journal:  Am Rev Respir Dis       Date:  1988-08

8.  Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association.

Authors:  M J Tobin; P J Cook; D C Hutchison
Journal:  Br J Dis Chest       Date:  1983-01

Review 9.  Molecular basis of alpha-1-antitrypsin deficiency.

Authors:  M Brantly; T Nukiwa; R G Crystal
Journal:  Am J Med       Date:  1988-06-24       Impact factor: 4.965

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  19 in total

Review 1.  Late onset genetic disease: where ignorance is bliss, is it folly to inform relatives?

Authors:  J T Wilcke
Journal:  BMJ       Date:  1998-09-12

2.  Transmitting genetic risk information in families: attitudes about disclosing the identity of relatives.

Authors:  J T Wilcke; N Seersholm; A Kok-Jensen; A Dirksen
Journal:  Am J Hum Genet       Date:  1999-09       Impact factor: 11.025

Review 3.  Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1997       Impact factor: 9.408

4.  Survival in severe alpha-1-antitrypsin deficiency (PiZZ).

Authors:  Hanan A Tanash; Peter M Nilsson; Jan-Ake Nilsson; Eeva Piitulainen
Journal:  Respir Res       Date:  2010-04-26

Review 5.  Alpha1-antitrypsin deficiency. 4: Molecular pathophysiology.

Authors:  D A Lomas; H Parfrey
Journal:  Thorax       Date:  2004-06       Impact factor: 9.139

6.  Clinical features and prognosis of life time non-smokers with severe alpha 1-antitrypsin deficiency.

Authors:  N Seersholm; A Kok-Jensen
Journal:  Thorax       Date:  1998-04       Impact factor: 9.139

7.  Genomics of Chronic Obstructive Pulmonary Disease (COPD); Exploring the SNPs of Protease-Antiprotease Pathway.

Authors:  Manish Kumar; Neetu Phougat; Sonam Ruhil; Sandeep Dhankhar; Meenakshi Balhara; Anil Kumar Chhillar
Journal:  Curr Genomics       Date:  2013-05       Impact factor: 2.236

8.  Cause-specific mortality in individuals with severe alpha 1-antitrypsin deficiency in comparison with the general population in Sweden.

Authors:  Hanan A Tanash; Magnus Ekström; Philippe Wagner; Eeva Piitulainen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-07-26

Review 9.  Alpha-1 antitrypsin deficiency is not a rare disease but a disease that is rarely diagnosed.

Authors:  Frederick J de Serres
Journal:  Environ Health Perspect       Date:  2003-12       Impact factor: 9.031

Review 10.  Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach.

Authors:  Robert A Stockley; Marc Miravitlles; Claus Vogelmeier
Journal:  Orphanet J Rare Dis       Date:  2013-09-24       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.